Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

Neurizon Secures Global Trademark Protection Across Key Markets

Highlights:

- **Neurizon has secured registered trademark protection for NEURIZON® across all priority global markets, including the United States, the European Union, the United Kingdom, Australia and Japan**
- **Completion of the US registration represents an important milestone supporting the Company's long-term commercialisation strategy in its primary value-creation market**
- **All registrations cover Class 42 services, including pharmaceutical research and development, clinical trial-related services and research and development in neurological therapeutics**
- **The trademark portfolio complements Neurizon's broader intellectual property strategy, including patent protection for its lead asset, NUZ-001**
- **Global brand and intellectual property protection across major pharmaceutical markets underpins Neurizon's evolution toward a globally positioned clinical-stage biotechnology company**

20 January 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that it has completed registered trademark protection for NEURIZON® across all priority global commercial markets, including the United States (US), the European Union (EU), the United Kingdon (UK), Australia and Japan.

The registrations collectively provide Neurizon with exclusive rights to use and protect its brand across the Company's core jurisdictions, supporting consistent global brand deployment and enforcement.

All registrations cover Class 42 services, including pharmaceutical research and development, clinical trial-related services, and research and development in neurological therapeutics. This scope aligns directly with Neurizon's current clinical programs and planned global activities as the Company advances its lead asset, NUZ-001, which is supported by Neurizon's expanding global patent portfolio.

The completion of Neurizon's global trademark registrations complements the Company's broader intellectual property strategy, which includes granted and pending patent protection for NUZ-001 across key pharmaceutical markets, and reinforces its evolution toward a globally positioned clinical-stage biotechnology company.

Completion of the US registration is particularly significant, as the US represents the Company's primary long-term value-creation and commercialisation market. The registration provides a strong foundation for future US operations, including engagement with clinical trial partners, strategic collaborators, licensees and other third-party service providers, as Neurizon progresses toward later-stage development.

Neurizon has progressively implemented appropriate registered trademark usage across its external communications over the course of 2025, ensuring compliance and consistency while finalising the full international registration suite.

Managing Director and Chief Executive Officer, Dr Michael Thurn commented: "Securing global trademark protection for NEURIZON strengthens the Company's intellectual property framework and supports consistent global brand deployment across key pharmaceutical markets. Together with our patent portfolio, this provides Neurizon with greater flexibility as we advance NUZ-001, including optionality should the Company elect to pursue commercialisation independently or in partnership."

The US, EU, UK and Japan collectively represent the largest global pharmaceutical markets and are typically prioritised by biotechnology companies for patent protection, regulatory approval and commercial deployment.

-ENDS-

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.

For further information, please contact:

Neurizon Therapeutics
Lidija Damjanovic
Marketing & Corporate Affairs
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504

Australia Investor Relations
Henry Jordan
Six Degrees Investor Relations
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538

U.S. Investor Relations
Matthew Selinger
Integrous Communications
Email: mselinger@integcom.us
Phone: +1 415-572-8152

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit https://investorhub.neurizon.com

Neurizon® is a registered trademark of Neurizon Therapeutics Limited